WHO Adds Three Ranbaxy Antiretrovirals To Prequalification List
Indian pharmaceutical company Ranbaxy Laboratories on Monday announced that the World Health Organization has added three of its antiretroviral drugs to WHO's list of prequalified antiretrovirals, Reuters India reports (Reuters India, 9/10).
Thedrugs will be available in compliance kits, which are designed toenhance regimen adherence. Each pack contains two fixed-dosecombination tablets of either lamivudine and zidovudine or lamivudineand stavudine, as well as a single tablet of efavirenz, according to aRanbaxy statement.The kits will help physicians ensure that patients comply withtreatment recommendations and reduce procurement and shipment costs.The lamivudine and zidovudine combination treatment, as well as theefavirenz formulation, are the first by any drug maker on WHO'sprequalification list, according to Ranbaxy.
Ranbaxy CEOMalvinder Mohan Singh said the company is "committed to using [its]experience and technology in developing innovative products to makevalue-added generic" antiretrovirals to "improve compliance and reducecosts." Singh added that the company believes the approvals will"benefit patients immensely" (Ranbaxy statement, 9/10).
Reprinted with permission from kaisernetwork.org. You can view theentire Kaiser DailyHIV/AIDS Report, search the archives, and sign up for email delivery at kaisernetwork.org/email . TheKaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service ofThe Henry J. Kaiser Family Foundation.